Therapeutic angiogenesis: Controlled delivery of angiogenic factors

Therapeutic Delivery

Volumn 3, Issue 6, 2012, Pages 693-714

  Chu, Hunghao ^a   Wang, Yadong ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANGIOGENIC FACTOR; ANGIOGENIC PROTEIN; ANGIOPOIETIN 1; COLLAGEN; FIBRIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GELATIN; HYALURONIC ACID; MACROGOL; NANOFIBER; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGINA PECTORIS; ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BOLUS INJECTION; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; GENE; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TUMOR VASCULARIZATION; VEGF GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84861801210     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.50     Document Type: Article

References (178)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2011 update. Circulation 123(4), e18-e209 (2011).
2. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature 451(7181), 937-942 (2008).
3. Grisar JC, Haddad F, Gomari FA, Wu JC. Endothelial progenitor cells in cardiovascular disease and chronic inflammation: From biomarker to therapeutic agent. Biomark. Med. 5(6), 731-744 (2011).
4. Hedman M, Hartikainen J, Yla-Herttuala S. Progress and prospects: Hurdles to cardiovascular gene therapy clinical trials. Gene Ther. 18(8), 743-749 (2011).
5. Ishikawa K, Tilemann L, Fish K, Hajjar RJ. Gene delivery methods in cardiac gene therapy. J. Gene Med. 13(10), 566-572 (2011).
6. Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc. Pathol. 12(6), 295-310 (2003).
7. Tayalia P, Mooney DJ. Controlled growth factor delivery for tissue engineering. Adv. Mater. 21(32-33), 3269-3285 (2009).
8. Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671-674 (1997).
9. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573), 435-439 (1996).
10. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Gene Dev. 13(9), 1055-1066 (1999).
11. Wijelath ES, Rahman S, Namekata M et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain. Circ. Res. 99(8), 853-860 (2006).
12. Jain RK. Molecular regulation of vessel maturation. Nat. Med. 9(6), 685-693 (2003).
13. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93(2), 662-670 (1994).
14. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102(8), 898-901 (2000).
15. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
16. Taniyama Y, Tachibana K, Hiraoka K et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 105(10), 1233-1239 (2002).
17. Nguyen DN, Green JJ, Chan JM, Langer R, Anderson DG. Polymeric materials for gene delivery and DNA vaccination. Adv. Mater. 21(8), 847-867 (2009).
18. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ. Res. 105(8), 724-736 (2009).
19. Henry TD, Grines CL, Watkins MW et al. Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50(11), 1038-1046 (2007).
20. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Circulation 109(22), 2692-2697 (2004).
21. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
22. Maherali N, Sridharan R, Xie W et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1(1), 55-70 (2007).
23. Leeper NJ, Hunter AL, Cooke JP. Stem cell therapy for vascular regeneration. Circulation 122(5), 517-526 (2010).
24. Structural Genomics Consortium, China Structural Genomics Consortium, Northeast Structural Genomics Consortium et al. Protein production and purification. Nat. Meth. 5(2), 135-146 (2008).
25. Lazarous DF, Shou M, Stiber JA et al. Pharmacodynamics of basic fibroblast growth factor: Route of administration determines myocardial and systemic distribution. Cardiovasc. Res. 36(1), 78-85 (1997).
26. Bethel A, Kirsch JR, Koehler RC, Finklestein SP, Traystman RJ. Intravenous basic fibroblast growth factor decreases brain injury resulting from focal ischemia in cats. Stroke 28(3), 609-616 (1997).
27. Laham RJ, Rezaee M, Post M et al. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution. Drug Metab. Dispos. 27(7), 821-826 (1999).
28. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell Physiol. 138(1), 215-220 (1989).
29. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407(6801), 242-248 (2000).
30. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4(12), 1317-1326 (1993).
31. Ruhrberg C, Gerhardt H, Golding M et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Gene Dev. 16(20), 2684-2698 (2002).
32. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling? In control of vascular function. Nat. Rev. Mol. Cell Biol. 7(5), 359-371 (2006).
33. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6), 735-745 (1998).
34. Kawamura H, Li X, Goishi K et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112(9), 3638-3649 (2008).
35. Harper SJ, Bates DO. VEGF-A splicing: The key to anti-Angiogenic therapeutics? Nat. Rev. Cancer 8(11), 880-887 (2008).
36. Manetti M, Guiducci S, Romano E et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis/novelty and significance. Circ. Res. 109(3), e14-e26 (2011).
37. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia. Circulation 118(1), 9-16 (2008).
38. Hedman M, Hartikainen J, Syvänne M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia. Circulation 107(21), 2677-2683 (2003).
39. Ripa RS, Wang Y, Jørgensen E, Johnsen HE, Hesse B, Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27(15), 1785-1792 (2006).
40. Alfranca A. VEGF therapy: A timely retreat. Cardiovasc. Res. 83(4), 611-612 (2009).
41. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 49(10), 1015-1026 (2007).
42. Tafuro S, Ayuso E, Zacchigna S et al. Inducible adeno-Associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc. Res. 83(4), 663-671 (2009).
43. Ornitz DM, Xu J, Colvin JS et al. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271(25), 15292-15297 (1996).
44. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 281(23), 15694-15700 (2006).
45. Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Proc. Natl Acad. Sci. USA 96(7), 3658-3663 (1999).
46. Sawada A, Shinya M, Jiang YJ, Kawakami A, Kuroiwa A, Takeda H. Fgf/MAPK signalling is a crucial positional cue in somite boundary formation. Development 128(23), 4873-4880 (2001).
47. Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl Acad. Sci. USA 89(15), 6896-6900 (1992).
48. Tigges U, Hyer EG, Scharf J, Stallcup WB. FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 135(3), 523-532 (2008).
49. Vitorino P, Meyer T. Modular control of endothelial sheet migration. Gene Dev. 22(23), 3268-3281 (2008).
50. Kinsella MG, Irvin C, Reidy MA, Wight TN. Removal of heparan sulfate by heparinase treatment inhibits FGF2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175(1), 51-57 (2004).
51. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF2 in the presence of fibrinogen requires avb3. Blood 104(12), 3635-3641 (2004).
52. Murakami M, Nguyen LT, Zhang ZW et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118(10), 3355-3366 (2008).
53. Murakami M, Nguyen LT, Hatanaka K et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J. Clin. Invest. 121(7), 2668-2678 (2011).
54. Hosaka A, Koyama H, Kushibiki T et al. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110(21), 3322-3328 (2004).
55. Takehara N, Tsutsumi Y, Tateishi K et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol. 52(23), 1858-1865 (2008).
56. Laham RJ, Chronos NA, Pike M et al. Intracoronary basic fibroblast growth factor (FGF2) in patients with severe ischemic heart disease: Results of a Phase I open-label dose escalation study. J. Am. Coll. Cardiol. 36(7), 2132-2139 (2000).
57. Bush M, Samara E, Whitehouse M et al. Pharmacokinetics and pharmacodynamics of recombinant FGF2 in a phase I trial in coronary artery disease. J. Clin. Pharmacol. 41(4), 378-385 (2001).
58. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Circulation 105(7), 788-793 (2002).
59. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF2). Brit. J. Pharmacol. 140(4), 637-646 (2003).
60. Lynch P, Lee TC, Fallavollita JA, Canty JM, Suzuki G. Intracoronary administration of AdvFGF-5 (fibroblast growth factor-5) ameliorates left ventricular dysfunction and prevents myocyte loss in swine with developing collaterals and ischemic cardiomyopathy. Circulation 116(Suppl. 11), I71-I76 (2007).
61. White AC, Lavine KJ, Ornitz DM. FGF9 and SHH regulate mesenchymal vegfa expression and development of the pulmonary capillary network. Development 134(20), 3743-3752 (2007).
62. Frontini MJ, Nong Z, Gros R et al. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat. Biotech. 29(5), 421-427 (2011).
63. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 130(20), 4769-4784 (2003).
64. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ. Res. 96(2), 172-179 (2005).
65. Faraone D, Aguzzi MS, Ragone G, Russo K, Capogrossi MC, Facchiano A. Heterodimerization of FGF-receptor 1 and PDGF-receptor-A: A novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 107(5), 1896-1902 (2006).
66. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ. Res. 100(5), 607-621 (2007).
67. Stratman AN, Schwindt AE, Malotte KM, Davis GE. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 116(22), 4720-4730 (2010).
68. Hellstrom M, Kal NM, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-b in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14), 3047-3055 (1999).
69. Kim J, Wu Q, Zhang Y et al. PDGF signaling is required for epicardial function and blood vessel formation in regenerating zebrafish hearts. Proc. Natl Acad. Sci. USA 107(40), 17206-17210 (2010).
70. Shyu K-G, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98(19), 2081-2087 (1998).
71. Tao Z, Chen B, Tan X et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc. Natl Acad. Sci. USA 108(5), 2064-2069 (2011).
72. Van Belle E, Witzenbichler B, Chen D et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis. Circulation 97(4), 381-390 (1998).
73. Tomita N, Morishita R, Taniyama Y et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 107(10), 1411-1417 (2003).
74. Ince H, Petzsch M, Kleine HD et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction. Circulation 112(Suppl. 9), I73-I80 (2005).
75. Hill JM, Bartunek J The end of granulocyte colony-stimulating factor in acute myocardial infarction? Circulation 113(16), 1926-1928 (2006).
76. Beohar N, Rapp J, Pandya S, Losordo DW. Rebuilding the damaged heart: The potential of cytokines and growth factors in the treatment of ischemic heart disease. J. Am. Coll. Cardiol. 56(16), 1287-1297 (2010).
77. Pola R, Ling LE, Silver M et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7(6), 706-711 (2001).
78. Jakobsson L, Franco CA, Bentley K et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 12(10), 943-953 (2010).
79. Gore AV, Swift MR, Cha YR et al. Rspo1/ Wnt signaling promotes angiogenesis via VEGFC/VEGFR3. Development 138, 4875-4886 (2011).
80. Markkanen JE, Rissanen TT, Kivelä A, Ylä-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart - gene therapy. Cardiovas. Res. 65(3), 656-664 (2005).
81. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Adv. Mater. 18(11), 1345-1360 (2006).
82. Chan AW, Whitney RA, Neufeld RJ. Kinetic controlled synthesis of pH-responsive network alginate. Biomacromolecules 9(9), 2536-2545 (2008).
83. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J. Thromb. Haemost. 5(3), 590-598 (2007).
84. Ruvinov E, Leor J, Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 31(16), 4573-4582 (2010).
85. Pitarresi G, Palumbo FS, Cavallaro G, Faré S, Giammona G. Scaffolds based on hyaluronan crosslinked with a polyaminoacid: Novel candidates for tissue engineering application. J. Biomed. Mater. Res. A 87(3), 770-779 (2008).
86. Darr A, Calabro A. Synthesis and characterization of tyramine-based hyaluronan hydrogels. J. Mater. Sci. Mater. Med. 20(1), 33-44 (2009).
87. Yeom J, Bhang SH, Kim BS et al. Effect of cross-linking reagents for hyaluronic acid hydrogel dermal fillers on tissue augmentation and regeneration. Bioconjugate Chem. 21(2), 240-247 (2010).
88. Tan H, Li H, Rubin JP, Marra KG. Controlled gelation and degradation rates of injectable hyaluronic acid-based hydrogels through a double crosslinking strategy. J. Tissue Eng. Regen. Med. 5(10), 790-797 (2011).
89. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 4(7), 528-539 (2004).
90. Yamanlar S, Sant S, Boudou T, Picart C, Khademhosseini A. Surface functionalization of hyaluronic acid hydrogels by polyelectrolyte multilayer films. Biomaterials 32(24), 5590-5599 (2011).
91. Hanjaya-Putra D, Bose V, Shen Y-I et al. Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix. Blood 118(3), 804-815 (2011).
92. Eyre DR. Collagen: Molecular diversity in the body's protein scaffold. Science 207(4437), 1315-1322 (1980).
93. Kanematsu A, Marui A, Yamamoto S et al. Type I collagen can function as a reservoir of basic fibroblast growth factor. J. Control. Release 99(2), 281-292 (2004).
94. Miyagi Y, Chiu LLY, Cimini M, Weisel RD, Radisic M, Li RK. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 32(5), 1280-1290 (2011).
95. Zhang J, Ding L, Zhao Y et al. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation 119(13), 1776-1784 (2009).
96. Gao J, Liu JZ, Gao Y et al. A myocardial patch made of collagen membranes loaded with collagen-binding human vascular endothelial growth factor accelerates healing of the injured rabbit heart. Tissue Eng. Part A 17(21-22), 2739-2747 (2011).
97. Giraudier S, Hellio D, Djabourov M, Larreta-Garde V. Influence of weak and covalent bonds on formation and hydrolysis of gelatin networks. Biomacromolecules 5(5), 1662-1666 (2004).
98. Saito H, Murabayashi S, Mitamura Y, Taguchi T. Characterization of alkali-treated collagen gels prepared by different crosslinkers. J. Mater. Sci. Mater. Med. 19(3), 1297-1305 (2008).
99. Li L, Okada H, Takemura G et al. Sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres persistently improves lower leg ischemia. J. Am. Coll. Cardiol. 53(25), 2378-2388 (2009).
100. Kohara H, Tabata Y. Enhancement of ectopic osteoid formation following the dual release of bone morphogenetic protein 2 and Wnt1 inducible signaling pathway protein 1 from gelatin sponges. Biomaterials 32(24), 5726-5732 (2011).
101. Tabata Y, Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 20(22), 2169-2175 (1999).
102. Hosaka A, Koyama H, Kushibiki T et al. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110(21), 3322-3328 (2004).
103. Takehara N, Tsutsumi Y, Tateishi K et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol. 52(23), 1858-1865 (2008).
104. Mintz PD, Mayers L, Avery N, Flanagan HL, Burks SG, Spotnitz WD. Fibrin sealant: Clinical use and the development of the University of Virginia tissue adhesive center. Ann. Clin. Lab. Sci. 31(1), 108-118 (2001).
105. Brown LF, Lanir N, Mcdonagh J, Tognazzi K, Dvorak AM, Dvorak HF. Fibroblast migration in fibrin gel matrices. Am. J. Pathol. 142(1), 273-283 (1993).
106. Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J. Cell Sci. 115(17), 3427-3438 (2002).
107. Oju J, Soo Hyun R, Ji Hyung C, Kim BS. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control. Release 105(3), 249-259 (2005).
108. Ehrbar M, Metters A, Zammaretti P, Hubbell JA, Zisch AH. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control. Release 101(1-3), 93-109 (2005).
109. Wood MD, Borschel GH, Sakiyama-Elbert SE. Controlled release of glial-derived neurotrophic factor from fibrin matrices containing an affinity-based delivery system. J. Biomed. Mater. Res. A 89(4), 909-918 (2009).
110. Smith JD, Chen A, Ernst LA, Waggoner AS, Campbell PG. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels. Bioconjugate Chem. 18(3), 695-701 (2007).
111. Drinnan CT, Zhang G, Alexander MA, Pulido AS, Suggs LJ. Multimodal release of transforming growth factor-b1 and the BB isoform of platelet derived growth factor from PEGylated fibrin gels. J. Control. Release 147(2), 180-186 (2010).
112. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies. Brit. J. Cancer 74(11), 1749-1756 (1996).
113. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 26(10), 552-558 (2008).
114. Webster R, Didier E, Harris P et al. PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 35(1), 9-16 (2007).
115. Rizzi SC, Ehrbar M, Halstenberg S et al. Recombinant protein-co-PEG networks as cell-Adhesive and proteolytically degradable hydrogel matrixes. Part II: Biofunctional characteristics. Biomacromolecules 7(11), 3019-3029 (2006).
116. Reid B, Tzeng S, Warren A, Kozielski K, Elisseeff J. Development of a PEG derivative containing hydrolytically degradable hemiacetals. Macromolecules 43(23), 9588-9590 (2010).
117. Zisch AH, Lutolf MP, Ehrbar M et al. Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J. 17(13), 2260-2262 (2003).
118. Tae G, Scatena M, Stayton PS, Hoffman AS. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J. Biomater. Sci. Polym. Ed. 17(1-2),187-197 (2006).
119. Phelps EA, Landázuri N, Thulé PM, Taylor WR, García AJ. Bioartificial matrices for therapeutic vascularization. Proc. Natl Acad. Sci. USA 107(8), 3323-3328 (2010).
120. Hutson CB, Nichol JW, Aubin H et al. Synthesis and characterization of tunable poly(ethylene glycol): Gelatin methacrylate composite hydrogels. Tissue Eng. Part A 17(13-14), 1713-1723 (2011).
121. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv. Drug Deliv. Rev. 54(1), 37-51 (2002).
122. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388(6645), 860-862 (1997).
123. Badi N, Lutz JF. PEG-based thermogels: Applicability in physiological media. J. Control. Release 140(3), 224-229 (2009).
124. Censi R, Vermonden T, Deschout H et al. Photopolymerized thermosensitive poly(HPMAlactate)-PEG-based hydrogels: Effect of network design on mechanical properties, degradation, and release behavior. Biomacromolecules 11(8), 2143-2151 (2010).
125. Gao Y, Ren FZ, Ding BY et al. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. J. Drug Target 19(7), 516-527 (2011).
126. Wang CH, Hwang YS, Chiang PR, Shen CR, Hong WH, Hsiue GH. Extended release of Bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 13(1), 40-48 (2011).
127. Zhang S, Holmes T, Lockshin C, Rich A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl Acad. Sci. 90(8), 3334-3338 (1993).
128. Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-Assembling peptide nanofibers. J. Clin. Invest. 116(1), 237-248 (2006).
129. Davis ME, Hsieh PCH, Takahashi T et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA 103(21), 8155-8160 (2006).
130. Lin YD, Yeh ML, Yang YJ et al. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 122(11 Suppl. 1), S132-S141 (2010).
131. Hartgerink JD, Beniash E, Stupp SI. Self-Assembly and mineralization of peptide-Amphiphile nanofibers. Science 294(5547), 1684-1688 (2001).
132. Rajangam K, Behanna HA, Hui MJ et al. Heparin binding nanostructures to promote growth of blood vessels. Nano Lett. 6(9), 2086-2090 (2006).
133. Rexeisen EL, Fan W, Pangburn TO et al. Self-Assembly of fibronectin mimetic peptide-Amphiphile nanofibers. Langmuir 26(3), 1953-1959 (2009).
134. Webber MJ, Tongers J, Newcomb CJ et al. Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair. Proc. Natl Acad. Sci. USA 108(33), 13438-13443 (2011).
135. Guo XM, Zhao YS, Chang HX et al. Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells. Circulation 113(18), 2229-2237 (2006).
136. Naito H, Melnychenko I, Didié M et al. Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114(Suppl. 1), I72-I78 (2006).
137. Hassan CM, Peppas NA. Structure and morphology of freeze/thawed PVA hydrogels. Macromolecules 33(7), 2472-2479 (2000).
138. Martens P, Anseth KS. Characterization of hydrogels formed from acrylate modified poly(vinyl alcohol) macromers. Polymer 41(21), 7715-7722 (2000).
139. Nilasaroya A, Poole-Warren LA, Whitelock JM, Martens JP. Structural and functional characterization of poly(vinyl alcohol) and heparin hydrogels. Biomaterials 29(35), 4658-4664 (2008).
140. Nuttelman CR, Mortisen DJ, Henry SM, Anseth KS. Attachment of fibronectin to poly(vinyl alcohol) hydrogels promotes NIH3T3 cell adhesion, proliferation, and migration. J. Biomed. Mater. Res. 57(2), 217-223 (2001).
141. Horiike S, Matsuzawa S Application of syndiotacticity-rich PVA hydrogels to drug delivery system. J. Appl. Polym. Sci. 58(8), 1335-1340 (1995).
142. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J. Control. Release 117(1), 68-79 (2007).
143. Cavalieri F, Chiessi E, Villa R et al. Novel PVA-based hydrogel microparticles for doxorubicin delivery. Biomacromolecules 9(7), 1967-1973 (2008).
144. Lu H, Xu X, Zhang M et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc. Natl Acad. Sci. USA 104(29), 12140-12145 (2007).
145. Garbern JC, Minami E, Stayton PS, Murry CE. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 32(9), 2407-2416 (2011).
146. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247-289 (2006).
147. Mooney DJ, Baldwin DF, Suh NP, Vacanti JP, Langer R. Novel approach to fabricate porous sponges of poly(d,l-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 17(14), 1417-1422 (1996).
148. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat. Biotech. 19(11), 1029-1034 (2001).
149. Ennett AB, Kaigler D, Mooney DJ. Temporally regulated delivery of VEGF in vitro and in vivo. J. Biomed. Mater. Res. A 79(1), 176-184 (2006).
150. Formiga FR, Pelacho B, Garbayo E et al. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J. Control. Release 147(1), 30-37 (2010).
151. Saif J, Schwarz TM, Chau DYS et al. Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. Arterioscler. Thromb. Vas. Biol. 30(10), 1897-1904 (2010).
152. No HK, Meyers SP, Prinyawiwatkul W, Xu Z. Applications of chitosan for improvement of quality and shelf life of foods: A review. J. Food Sci. 72(5), R87-R100 (2007).
153. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 62(1), 59-82 (2010).
154. Schiffman JD, Schauer CL. Cross-linking chitosan nanofibers. Biomacromolecules 8(2), 594-601 (2006).
155. Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R. Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG. Biomacromolecules 8(3), 833-842 (2007).
156. Boddohi S, Killingsworth CE, Kipper MJ. Polyelectrolyte multilayer assembly as a function of pH and ionic strength using the polysaccharides chitosan and heparin. Biomacromolecules 9(7), 2021-2028 (2008).
157. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5(4), 387-391 (1999).
158. Liu ZG, Jiao YP, Liu FN, Zhang ZY. Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. J. Biomed. Mater. Res. A 83A(3), 806-812 (2007).
159. Yang SJ, Chang SM, Tsai KC, Chen WS, Lin FH, Shieh MJ. Effect of chitosan-Alginate nanoparticles and ultrasound on the efficiency of gene transfection of human cancer cells. J. Gene Med. 12(2), 168-179 (2010).
160. Verheul RJ, Slutter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J. Control. Release 156(1), 46-52 (2011).
161. Mao HQ, Roy K, Troung-Le VL et al. Chitosan-DNA nanoparticles as gene carriers: Synthesis, characterization and transfection efficiency. J. Control. Release 70(3), 399-421 (2001).
162. Mao SR, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 62(1), 12-27 (2010).
163. Tang DW, Yu SH, Ho YC, Mi FL, Kuo PL, Sung HW. Heparinized chitosan/poly(g-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin. Biomaterials 31(35), 9320-9332 (2010).
164. Tan Q, Tang H, Hu JG et al. Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds. Int. J. Nanomed. 6, 929-942 (2011).
165. Maherani B, Arab-Tehrany E, Mozafari MR, Gaiani C, Linder M. Liposomes: A review of manufacturing techniques and targeting strategies. Curr. Nanosci. 7(3), 436-452 (2011).
166. Ye L, Haider HK, Esa WB et al. Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease. J. Cell. Mol. Med. 14(1-2):323-336 (2010).
167. Scott RC, Rosano JM, Ivanov Z et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 23(10), 3361-3367 (2009).
168. Singh S, Wu BM, Dunn JCY. Delivery of VEGF using collagen-coated polycaprolactone scaffolds stimulates angiogenesis. J. Biomed. Mater. Res. A 100 (3), 720-727 (2012).
169. Du FY, Wang H, Zhao W et al. Gradient nanofibrous chitosan/poly epsilon-caprolactone scaffolds as extracellular microenvironments for vascular tissue engineering. Biomaterials 33(3), 762-770 (2012).
170. Davies NH, Schmidt C, Bezuidenhout D, Zilla P. Sustaining neovascularization of a scaffold through staged release of vascular endothelial growth factor-A and platelet-derived growth factor-BB. Tissue Eng. Part A 18(1-2), 26-34 (2012).
171. Zern BJ, Chu H, Wang Y. Control growth factor release using a self-Assembled [polycation:heparin] complex. PLoS ONE 5(6), e11017 (2010).
172. Chu H, Gao J, Chen CW, Huard J, Wang Y. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. Proc. Natl Acad. Sci. USA 108(33), 13444-13449 (2011).
173. Chu H, Johnson NR, Mason NS, Wang Y. A [polycation:heparin] complex releases growth factors with enhanced bioactivity. J. Control. Release 150(2), 157-163 (2011).
174. Meller R. The role of the ubiquitin proteasome system in ischemia and ischemic tolerance. Neuroscientist 15(3), 243-260 (2009).
175. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation 122(18), 1862-1875 (2010).
176. Marzouk SA, Buck RP, Dunlap LA, Johnson TA, Cascio WE. Measurement of extracellular pH, K+, and lactate in ischemic heart. Anal. Biochem. 308(1),
177. Mehta JL, Li DY. Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain? Cardiovasc. Res. 43(2), 291-299 (1999).
178. Le KN, Hwang CW, Tzafriri AR, Lovich MA, Hayward A, Edelman ER. Vascular regeneration by local growth factor release is self-limited by microvascular clearance. Circulation 119(22), 2928-2935 (2009).